Peutz-Jeghers syndrome (PJS) is an autosomal dominant disorder characterized by the presence of multiple gastrointestinal polyps and an increased risk for various types of cancers. Inactivating germline mutations of the LKB1 gene, which encodes a serine/threonine kinase, are responsible for the majority of PJS cases. Here, we show that the heteromeric complex containing the molecular chaperones Hsp90 and Cdc37/p50 interacts with the kinase domain of LKB1. Treatment of cells with either geldanamycin or novobiocin, two pharmacological inhibitors of Hsp90 causes the destabilization of LKB1. Furthermore, geldanamycin treatment leads to the ubiquitination and the rapid degradation of LKB1 by the proteasome-dependent pathway. In addition, we found that a LKB1 point mutation identified in a sporadic testicular cancer, weakens the interaction of LKB1 with both Hsp90 and Cdc37/p50 and enhances its sensitivity to the destabilizing effect of geldanamycin. Collectively, our results demonstrate that the Hsp90/Cdc37 complex is a major regulator of the stability of the LKB1 tumor suppressor. Furthermore, these data draw attention to the possible adverse consequences of antitumor drugs that target Hsp90, such as antibiotics related to geldanamycin, which could disrupt LKB1 function and promote the development of polyps and carcinomatous lesions. Oncogene (2003) 22, 9165-9175.
Introduction
The Peutz-Jeghers syndrome (PJS) is a dominantly inherited syndrome characterized by the presence of hamartomatous polyps in the gastrointestinal tract and by melanin spots on the lips, buccal mucosa and digits (Peutz, 1921; Jeghers et al., 1949) . Patients with PJS have an increased risk of developing various cancers, particularly of the breast, intestine, testis, cervix and pancreas (Giardiello et al., 1987; Spigelman et al., 1989) . Germline mutations of the LKB1 gene (also called STK11) located on chromosome 19pl3.3 and encoding a serine/threonine kinase are the underlying genetic cause of the majority of PJS cases (Hemminki et al., 1998; Jenne et al., 1998) . These mutations which include small deletions and point mutations, disrupt LKB1 function (Mehenni et al., 1998; Ylikorkala et al., 1999) . The loss of heterozygosity (LOH) at the LKB1 locus found in a fraction of PJS polyps together with the inactivating nature of the PJS germline mutations are consistent with a tumor suppressor role for LKB1 (Hemminki et al., 1998; Avizienyte et al., 1999) . While rare somatic mutations of LKB1 have been identified in sporadic cancers, inactivation of both LKB1 alleles appears a relatively common event in adenocarcinoma of the lung (Sanchez-Cespedes et al., 2002) .
The LKB1 gene has been conserved across species and orthologs have been identified in mouse, Xenopus (Xeek1), Drosophila and Caenorhabditis elegans ( par-4) (Su et al., 1996; Smith et al., 1999; Watts et al., 2000; Martin and St Johnston, 2003) . LKB1 is widely expressed during embryonic development and mice homozygous for an inactivating LKB1 mutation die at midgestation with multiple developmental defects including abnormal vasculogenesis, neural tube malformation and mesenchymal apoptosis (Ylikorkala et al., 2001) . Immunostaining of LKB1 in mouse and human small intestine has revealed that LKB1 is expressed in two distinct topographic regions, the crypts which contain rapidly dividing stem cells and the tip of the villi where cells undergo apoptosis and are shed into the lumen (Karuman et al., 2001; Bardeesy et al., 2002) . Furthermore, LKB1 is also detected in the epithelium of the gastric mucosa. Consistent with these data suggesting a role for LKB1 during morphogenesis of the stomach and the intestine, several groups have recently reported that heterozygous LKB1 knockout mice develop multiple gastrointestinal polyps which are histologically similar to the hamartomas found in PJS patients (Bardeesy et al., 2002; Jishage et al., 2002; Miyoshi et al., 2002; Rossi et al., 2002) .
Human LKB1 consists of 433 amino acids and contains both a nuclear localization signal in its N-terminal noncatalytic domain and a prenylation consensus sequence in its C-terminus (Smith et al., 1999; Collins et al., 2000; Sapkota et al., 2001) . LKB1 is located in the nucleus of cells, but is also detected in the cytoplasm and at cell membranes (Smith et al., 1999; Collins et al., 2000; Sapkota et al., 2001) . The subcellular localization of LKB1 is regulated via its interaction with specific proteins such as LIP-1 (Smith et al., 2001) , a novel molecule displaying leucine-rich repeats, and STRADa, a STE20-like pseudokinase (Baas et al., 2003) . Both LIP-1 and STRADa anchor LKB1 in the cytoplasm. However, LIP-1 forms a ternary complex with LKB1 and Smad-4 to regulate the TGF-b signalling (Smith et al., 2001) while STRADa is phosphorylated by LKB1 and enhances the catalytic activity of LKB1 (Baas et al., 2003) . Although the signalling pathways which regulate LKB1 activity are yet poorly understood, it is known that in response to ionizing radiation, the ataxia-telangectasia mutated (ATM) kinase phosphorylates LKB1 at Thr366 (Sapkota et al., 2002) , whereas upon stimulation with agonists of adenylate cyclase or growth factors, both the cAMP-dependent protein kinase A and p90 RSK phosphorylates LKB1 at Ser428 (Sapkota et al., 2001) . It has been further proposed that LKB1 is a mediator of p53-dependent apoptosis (Karuman et al., 2001) , is necessary for the brahma-related gene (BRG1)-induced cell cycle arrest (Marignani et al., 2001) and is involved in the regulation of the NF-kB pathway via its interaction with a novel protein called FLIP-1 (Liu et al., 2003) . Finally, previous studies have revealed that the reintroduction of LKB1 in tumor cells which lack expression of LKB1 induces a G1 cell cycle arrest mediated by the CDK inhibitor p21 WAFÀ1/CIP1 , thus reinforcing the notion that LKB1 acts as a tumor suppressor (Shen et al., 2002; Tiainen et al., 1999 Tiainen et al., , 2002 .
Mutations in par-4, the C. elegans orthologue of LKB1, disrupt several aspects of embryonic asymmetry that are required for the determination of cell fates in early blastomeres (Watts et al., 2000 and references herein) . par-4 mutation also interfere with the determination of the worm intestine, an intriguing result considering the fact that intestinal hamartomatous polyps are one of the cardinal clinical features of PJS (Watts et al., 2000 and references herein) . The past year revealed that Drosophila LKB1 is involved in the establishment of polarity in the germ line and in epithelial follicular cells (Martin and St Johnston, 2003) . Furthermore, Blumer and co-workers have recently showed that LKB1 interacts with, and phosphorylates (Blumer et al., 2003) , the activator of Gprotein signalling 3 (AGS3), a receptor-independent activator of G-protein signalling known to be involved in spindle positioning during asymmetric cell divisions (Blumer et al., 2003 and references herein) . These results indicate that LKB1 functions have been evolutionarily conserved and that hamartomas and tumors which develop in PJS patients could result from a perturbation of either formation or maintenance of epithelial polarity.
Here, we provide evidence that the binding of molecular chaperones Hsp90 and Cdc37 to LKB1 is critical for LKB1 stabilization. In addition, treatment with geldanamycin, an antibiotic that disrupts the complex formed between LKB1 and Hsp90, promotes ubiquitination of LKB1 and its subsequent degradation by the proteasome. These data suggest that the association of Hsp90/Cdc37 to LKB1 is a rate-limiting event that controls LKB1's biological activity.
Materials and methods

Vectors
The pSG-Flag eukaryotic expression vector used in this study was derived from the pSG5 plasmid (Stratagene) and contained the sequence coding for the Flag epitope tag. The human LKB1 (hLKB1) cDNA was PCR amplified from human intestinal cDNA using the following primers:
Forward:
0 . The PCR fragment was digested with BglII and subcloned into the BamHI restriction site of the pSG5/Flag plasmid. The hLKB1 insert was entirely sequenced and corresponded to the wild-type sequence. The pSG/Flag-LKB1 vector encodes the human LKB1 fused N-terminally to the Flag epitope. The pSG/Flag control plasmid contains the human LKB1 cDNA carrying a missense mutation that replaces the 9th codon by a stop codon.
To generate the pSG/Flag-D243 plasmid which encodes a truncated mutant of LKB1 (1-243 amino acids), the pSG/ Flag-LKB1 plasmid was digested with BstEII which cuts at codon 241 of the LKB1 coding sequence. After treatment with T4 DNA polymerase, an adapter containing a stop codon at codon 243 was ligated into the BstEII digested vector. To generate the pSG/Flag-D88 plasmid, the pSG/Flag-LKB1 plasmid was digested with BamHI which cuts at codon 88 of the LKB1 coding sequence, treated with the Klenow DNA polymerase (Biolabs) and then digested with BglII. This cDNA fragment which encodes a truncated form of LKB1 (88-433 amino acids) was subcloned into the pSG/Flag plasmid. The pSG/Flag-D146-186 was obtained by partial digestion with XmnI of pSG/Flag-LKB1 followed by a SgraI digestion (which released a cDNA fragment coding for the region comprised between amino acids 147-185 of LKB1), treated with the Klenow enzyme and then religated. The pSG/Flag-D317 plasmid was generated by directed mutagenesis (U.S.E Mutagenesis Kit from Amersham Pharmacia Biotec Inc.) using an oligonucleotide which contains a stop codon at codon 317:
The following missense mutations of LKB1 were obtained by directed mutagenesis as described above, using the following oligonucleotides: Cell line and transfection assays HBL100 human breast epithelial cell line was cultured in Dulbecco's modified Eagle's medium with 10% of heatinactivated fetal bovine serum supplemented with 50 U/ml of penicillin and 50 U/ml of streptomycin and incubated at 371C in 5% CO 2 . Plasmids encoding LKB1 cDNAs were transfected into cells at 80% of confluence using ExGen 500 (Euromedex) as a transfection reagent, according to the manufacturer's instructions.
Protein analyses
Cells were lysed 48 h post-transfection in a lysis buffer containing: 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 2 mM EDTA and 1% Nonidet P-40, supplemented with a mixture of proteases and phosphatases inhibitors. After 15 min on ice, lysates were cleared by centrifugation at 14 000 r.p.m. for 15 min at 41C. Depending on the experiment, either the soluble cellular fraction or both the soluble and insoluble fractions (the insoluble fraction corresponds to the pellet) were analysed by Western blotting. Protein concentration was determined by a modified Bradford assay (Bio-Rad). Proteins were resuspended in the Laemmli buffer (20 mM Tris-HCl (pH 6.8), 2% SDS, 20% glycerol, 20 mg of bromophenol blue per ml) in the presence of 1.4 M of 2-mercaptoethanol and separated on a SDS-PAGE polyacrylamide gels, then transferred to polyvinylidenedifluoride (PVDF) membranes (Immobilon P Millipore). Membranes were incubated with the appropriate antibody as previously described.
To solubilize the NP40 insoluble cellular fraction, cells were lysed in a buffer containing: 20 mM Tris-HCl (pH 7.5), 1% SDS, 1% Nonidet P-40, 150 mM NaCl, 10 mM iodoacetamide and a mixture of protease and phosphatase inhibitors. After clearing by centrifugation, the supernatant was treated with bensonase (5 UI/ml) (Sigma) for 20 min on ice. After cell lysis, the buffer was diluted up to 0.3% of SDS and used for immunoprecipitation with the anti-Flag antibody. 1 mg of soluble proteins was incubated in 1 ml of lysis buffer in the presence of 1 mg of antibody. After 2 h of incubation at 41C, immune complexes were collected on protein G coupled to sepharose beads (Amersham Pharmacia Biotech) and washed three times in lysis buffer. The resulting complexes were resuspended in Laemmli buffer, boiled for 5 min, separated on a SDS-PAGE polyacrylamide gel. The gel was either silverstained (Bio-Rad reagents) or transferred on PVDF membranes for Western blotting analyses. For large-scale purification of LKB1-associated proteins, the equivalent of 10 immunoprecipitations was loaded in one well of the polyacrylamide gel and resolved by SDS-PAGE. The proteins were then revealed by Coomassie staining (Coomassie stain solution, Bio-Rad). Protein band was excised from the gel and kept in 10% ethanol for mass spectrometry analysis.
For coimmunoprecipitation experiments of endogenous LKB1 and Hsp90 proteins, sodium molybdate (20 mM final concentration, purchased from Sigma) was added both in the lysis and washing buffers.
LKB1 autokinase assay
Flag-LKB1 protein was immunoprecipitated with the antiFlag antibody and the immunocomplex was incubated in a 30 ml mixture reaction containing 20 mM HEPES pH 7.4, 10 mM MgCl 2 , 10 mM MnCl 2 , 10 mM b-glycerophosphate, 1 ml [g-32 P]ATP (10 mCi/ml-4500 Ci/mmol, ICN). After 30 min at 301C, the reaction was stopped by addition of 6 ml of the SDS sample buffer (120 mM Tris-HCl pH 6.8, 4% SDS, 2% glycerol, 0.01% bromophenol blue, 10% b-mercaptoethanol). Samples were electrophoresed on a SDS-PAGE polyacrylamide gel (10%), transferred to PVDF membrane and analysed by autoradiography and by Western blot.
Mass spectrometry analysis
Mass spectrometry analyses and similarity search in SWISS-PROT/TrEMBL was performed by the Swiss-2D Service company (Geneva).
Treatment with Hps90 and protease inhibitors
Geldanamycin (GA), novobiocin, the proteasome inhibitor benzyloxycarbonyl-Leu-Leu-Leu-aldehyde (MG132) and Pepstatin A were purchased from Sigma. Leupeptin was purchased from Alexis Coger. Stock solutions were prepared as follows: GA was resuspended in DMSO at the final concentration of 400 mM and used at the final concentration of 2 mM; novobicin was resuspended in water and used at a final concentration of 1 mM; MG132 was dissolved in water at the final concentration of 50 mM and used at the final one of 50 mM; Pepstatin A was prepared in methanol at 1.45 mM, final concentration, and used at the final one of 100 mM; Leupeptin was dissolved in water at 20 mM final concentration and used after a 1000-fold dilution. Drugs or vehicles were added directly in the cell culture media for the times indicated in the figure legends. Cells were exposed to drugs 48 h post-transfection.
Pulse-chase analysis
At 48 h post-transfection, transfected HBL100 cells were washed with methionine/cysteine-free DMEM (Sigma). Culture medium was then replaced with methionine/cysteine-free DMEM containing 10% SVF, penicillin/streptomycin antibiotics and 62. free DMEM containing 10% SVF, penicillin/streptomycin antibiotics and then either lysed immediately or incubated in complete medium in the presence of either GA or DMSO for the indicated times prior to cell lysis. Flag-LKB1 protein was immunoprecipitated from the cleared lysates with the anti-Flag antibody as previously described and separated by SDS-PAGE. Gels were dried and exposed for autoradiography. The relative amount of radiolabelled LKB1 protein was quantified by densitometry using the fluorimeter FluorS and the Quantity One software (BioRad, Ivry, France).
Results
To characterize proteins that interact with LKB1, we transfected the mammary epithelium cell line HBL100 with an eukaryotic expression vector expressing the human LKB1 protein tagged with an N-terminal Flag epitope. As a control, we also expressed in the same cell line the N-terminally flagged docking protein FRS2 (Kouhara et al., 1997) . LKB1 was immunoprecipitated from transfected cells and the immunoprecipitate was fractionated by SDS-PAGE and silver stained to visualize proteins which bind to LKB1. In these conditions, a band migrating at approximately 90 kDa was repeatedly detected in the lane corresponding to LKB1 but not in the FRS2 control ( Figure 1a ). Western blotting with the anti-Flag antibody confirmed that both LKB1 and FRS2 were correctly immunoprecipitated in these conditions and expressed at similar levels ( Figure 1b) . To determine the identity of the 90 kDa protein, we pooled several immunoprecipitates to enrich the 90 kDa protein and excised the band from the gel after Coomassie-staining. MALDI mass spectrometry of the purified material revealed that this band corresponds to the cytosolic molecular chaperone heat-shock protein 90 alpha (Hsp90a). Previous studies have shown that Hsp90 isoforms a and b display very similar functions (Pearl and Prodromou, 2000; Young et al., 2001) and in the rest of the study, we have used immunological reagents which recognize both isoforms. To confirm that Hsp90 forms a specific complex with LKB1, we immunoprecipitated LKB1 with the Flag antibody and probed the Western blot with an anti-Hsp90 serum. As shown in Figure 1c , a band corresponding to Hsp90 was clearly detected in the LKB1 lane and not in the FRS2 control.
Hsp90 is an ubiquitous molecule that plays a key role in the stabilization and the conformational regulation of signalling effectors such as steroid hormone receptors and protein kinases (Pearl and Prodromou, 2000; Young et al., 2001) . Hsp90 cellular functions require its association with a set of specific cofactors which ensures the binding selectivity of Hsp90 to its targets and assists its chaperone activity. The co-chaperone Cdc37/p50 interacts with Hsp90 and evidence has been provided that Cdc37/p50 acts as an adaptator subunit Hsp90/Cdc37 regulate LKB1 stability P Nony et al that binds to, and is needed, for the activity of an array of protein kinases (Hunter and Poon, 1997) . To examine whether LKB1 is also associated with Cdc37/p50, LKB1 was immunoprecipitated and Western blotted with an anti-Cdc37 antibody. As shown in Figure 1d , Cdc37 was found in the LKB1 immunoprecipitates but not in the FRS2 control, thus confirming that LKB1 forms a complex with Cdc37/p50. To further investigate the relevance of the LKB1-Hsp90 interaction, we analysed whether endogenous LKB1 binds to Hsp90. For that purpose, we lysed HBL100 cells in a buffer containing sodium molybdate at a concentration of 20 mM to preserve the putative complex formed with Hsp90 (Stancato et al., 1997) . Endogenous LKB1 was immunoprecipitated with an antibody raised against the N-terminus part of the protein (Figure 2a) , and we confirmed that endogenous LKB1 coimmunoprecipitated with Hsp90 in these conditions (Figure 2b ). It has been previously established that Hsp90 interacts with the Raf-1 kinase (Perdew et al., 1997; Stancato et al., 1997) . In accordance with these results, we found that Hsp90 co-precipitates with Raf-1, but not with the microtubule-binding protein EB1, thus ensuring the specificity of our immunoprecipitation conditions.
We next defined the region in LKB1 responsible for its interaction with Hsp90. A series of four LKB1 deletion mutants was generated and expressed in HBL100 cells (Figure 3a) . Immunoblotting with the anti-Flag antibody confirmed that these LKB1 mutants were expressed after transfection, although the expression level of D243 and D317 mutants was lower than for the two other LKB1 mutants (Figure 3b ). We also checked that these four truncation products were immunoprecipitated with the anti-Flag antibody (data not shown). To analyse their binding properties, LKB1 truncation products were immunoprecipitated and Western blotted with an anti-Hsp90 antibody. As shown in Figure 3c , deletion of the noncatalytic carboxyterminal region (D317) did not prevent the binding of Hsp90. However, the D243 mutant formed a complex with Hsp90, thus indicating that both the N-terminal region and a portion of the kinase domain of LKB1 are sufficient for the interaction with Hsp90. In addition, truncation of the N-terminal amino acids of LKB1 (D88) significantly reduced its interaction with Hsp90 considering that the relative expression level of this mutant is lower compared to LKB1 wild-type and to the D243 mutant. Finally, an internal deletion within the catalytic domain (D146-186) abolished the association with Hsp90. Taken together, these results indicate that the LKB1 kinase domain but not the carboxy-terminal region is required for the interaction with Hsp90.
We next investigated whether LKB1 mutations located within the catalytic domain and found either in a PJS patient (M136R) (Olschwang et al., 2001) or in a sporadic testicular tumor (G163D) interfere with the binding of Hsp90 and Cdc37/ p50. The G163D mutation is located within the region of the LKB1 kinase domain that we found to be crucial for the binding to Hsp90. We also included in this analysis an LKB1 mutant (K78A) devoid of catalytic activity. Immunoprecipitation of LKB1 mutants with the anti-Flag antibody followed by immunoblotting with both the anti-Hsp90 and Cdc37/p50 antibodies revealed that the mutation G163D reduced drastically the association with both Hsp90 and Cdc37/p50 whereas the K78A and the PJS mutations did not affect significantly the interaction of LKB1 with the Hsp90/ Cdc37 complex (Figure 4a ). Although, Hsp90 was hardly detected in association with Flag-LKB1 (G163D) using this procedure, metabolic labelling of transfected HBL100 cells showed that LKB1-G163D retained some capacity to interact with Hsp90, albeit with a reduced efficiency compared to LKB1 wild type (data not shown). We further assessed the LKB1 catalytic activity of these mutants by measuring the ability of LKB1 to autophosphorylate. As already Hsp90/Cdc37 regulate LKB1 stability P Nony et al described, the K78A mutation compromised the LKB1 autokinase activity (Figure 4c) . Furthermore, the PJS mutation M136R disrupted LKB1 autokinase activity, while the G163D mutant retained a weak autocatalytic activity as previously reported (Figure 4c ). Thus, these results indicate that the binding of Hsp90/Cdc37 to LKB1 does not depend on LKB1 protein kinase activity and also strengthen the notion that the LKB1 kinase domain contains the major regions of contact necessary for the assembly of Hsp90/Cdc37 complex.
The drug geldanamycin (GA) interacts with the NH2-terminal ATP/ADP binding pocket of Hsp90 and acts as a competitive inhibitor of its ATPase activity, thereby leading to the dissociation and eventual degradation of Hsp90 client proteins (Whitesell et al., 1994; Schulte et al., 1995; Prodromou et al., 1997; Stebbins et al., 1997) . To examine whether LKB1 stability depends on Hsp90-binding, HBL100 cells were transfected either with a vector expressing the Flag-LKB1 or the Flag-FRS2 and then treated with 2 mM of GA. As shown in Figure 5a , 2 h of GA treatment caused a marked diminution of the level of LKB1 whereas it had no significant effect on the stability of FRS2 which does not interact with Hsp90. To validate these results, we used novobiocin, another known Hsp90 inhibitor which is structurally unrelated to GA and binds to a recently characterized ATP-binding domain located in the Cterminal part of Hsp90 (Marcu et al., 2000) . As displayed in Figure 5b , novobiocin treatment of transfected HBL100 cells led to a significant decrease of LKB1, whereas novobiocin treatment did not substantially alter the level of the FRS2 protein.
Quantification of the amount of LKB1 normalized with the amount of actin indicates that 8 and 24 h of novobiocin treatment induced a 60 and 50% decrease in the levels of LKB1, respectively. Next, we monitored the degradation of LKB1 upon GA treatment and determined its half-life. HBL100 cells expressing Flag-LKB1 were labelled with a mixture of [
35 S] methionine/ [ 35 S] cysteine and then chased with a nonradioactive medium at various times. In these experiments, either GA or the diluent DMSO were added together with the nonradioactive medium at the time of the chase. As shown in Figure 5c , LKB1 was found to be relatively stable in cells treated with DMSO, whereas this half-life was dramatically shortened in cells treated with GA. Pulse-chase experiments also confirmed that GA led to a very rapid disassembly of the Hsp90-LKB1 complex, detectable as soon as 5 min after the addition of the compound to the culture medium (Figure 5c ). We confirmed by Western blotting that the band detected by autoradiography at 90 kDa and visualized in Figure 5c corresponded to Hsp90 (data not shown). To compare the respective half-lives of both LKB1 and G163D mutants, we carried out pulse-chase experiments with HBL100 transfectants and then quantified the levels of radioactive material. As shown in Figure 5d , the half-life of wild-type LKB1 was 2 h whereas the half-life of LKB1-G163D mutant was 30 min, a finding in agreement with the observed reduced affinity of Hsp90 to this mutant form of LKB1. Finally, we examined the effects of GA on endogenous LKB1 and found that treatment of HBL100 cells with 2 mM of GA resulted in a drastic decrease of the amount of LKB1 (Figure 5e ). During the course of this study, we noticed that the diminution of endogenous LKB1 required a longer duration of incubation with GA, an observation which suggests that endogenous LKB1 has a longer half-life than exogenous Flag-LKB1. Taken together, these results indicate that Hsp90 binding is necessary for LKB1 stabilization.
A number of studies have now demonstrated that GA-induced degradation of Hsp90 target proteins is preceded by their ubiquitination and subsequent targeting to the proteasome (Mimnaugh et al., 1996; Whitesell et al., 1997) . To investigate whether a similar mechanism could account for GA-mediated decay of LKB1, we blocked the proteasome function with a specific inhibitor, MG132. When HBL100 cells expressing Flag-LKB1 were incubated with GA plus MG132 and lysed in a buffer containing 1% of NP-40, we did not observe a significant increase of LKB1 in the soluble fraction (Figure 6a) . However, as previously described for other protein kinases known to bind Hsp90 such as PDK-1 and MOK (Miyata et al., 2001 ; Fujita et al.,
2002) treatment with both GA and MG132 led to a drastic increase of the level of LKB1 in the insoluble fraction (Figure 6b ), whereas other protease inhibitors did not show any effects (Figures 6a,b) . These data indicate that MG132 stabilizes LKB1 upon GA treatment, thus supporting the hypothesis that LKB1 undergoes proteosomal degradation when the LKB1-Hsp90 complex is dissociated.
Targeting of proteins to the proteasome requires their tagging by the ubiquitin system which covalently conjugates polyubiquitin chains onto proteins destined to proteolysis (Ciechanover and Schwartz, 1998) . Our results obtained with the proteasome inhibitor MG132 prompted us to study whether LKB1 was ubiquitinated when the complex formed with Hsp90 was disrupted. For that purpose, HBL100 cells were either transfected with a vector expressing the Flag-LKB1 or cotransfected with the Flag-LKB1 expressing vector and a plasmid coding for ubiquitin. Western blotting with the anti-Flag antibody revealed a series of bands forming a smear above LKB1 in the lanes corresponding to the cells Hsp90/Cdc37 regulate LKB1 stability P Nony et al treated with both GA and MG132 (Figure 7a ). When the cells were cotransfected with the vectors expressing LKB1 and ubiquitin, these bands were detected in the control lanes (DMSO and GA), but were markedly increased in the lane corresponding to the GA plus MG132 treatment. These data are in agreement with the idea that MG132 prevents the proteolysis of unstable multiubiquitinated forms of LKB1. To confirm these results, we transfected HBL100 cells using the same conditions and performed an immunoprecipitation with the anti-Flag antibody followed by a Western blot with an antiubiquitin antibody. A smear consistent with the covalent attachment of ubiquitin chains to LKB1 was detected in cells transfected with the Flag-LKB1 vector and treated with GA plus MG132, and this smear of bands was clearly enriched in cells cotransfected with both vectors and incubated with GA plus MG132 (Figure 7b ). Collectively, these results provide evidence that LKB1 is ubiquitinated and degraded by the proteasome when Hsp90 is released by the action of GA.
Discussion
In this work, we have provided evidence that the molecular chaperones Hsp90 and Cdc37 bind to human LKB1 and regulate its stability. Using LKB1 truncation and deletion mutants, we found that the kinase domain 35 S]cysteine and chased with nonradioactive medium for the indicated times in the presence of GA (lanes 16-19) or in absence (DMSO, At the end of the indicated times (T0), cells were lysed and the Flag-LKB1 protein was immunoprecipitated using the anti-Flag M2 antibody and resolved on a polyacrylamide gel. The dried gel was autoradiographed. The Hsp90 protein which coimmunoprecipitates with LKB1 is also revealed as indicated, as confirmed by Western blot experiment (data not shown). (d) HBL100 cells expressing either LKB1 wild type or the G163D mutant were metabolically labelled, chased with nonradiocative medium and the radioactive material was then quantified. Similar results were obtained in two independent experiments. (e) Endogenous LKB1 protein is also destabilized by GA treatment. HBL100 cells were treated for 24 h in the presence of 2 mM of geldanamycin (GA) or its absence (DMSO), lysed and endogenous LKB1 was immunoprecipitated. Immunoprecipitation reactions were analysed by Western blot using an anti-LKB1 antibody Hsp90/Cdc37 regulate LKB1 stability P Nony et al of LKB1 is required for the association with Hsp90, whereas the 116 amino acids of the C-terminus are dispensable. Our results also suggest that a portion of the LKB1 N-terminal part might be involved in the binding to Hsp90. However, we have not precisely mapped the boundary of the N-terminal region involved in this association and it is possible that only the 39 amino acids of the LKB1 kinase domain which are lacking in the LKB1-D88 truncated mutant, are involved in this process. An LKB1 mutation identified in a testicular tumor (G163D) and located within the catalytic core domain impairs the formation of the LKB1/Hsp90-Cdc37 heterocomplex, thus reinforcing the idea that Hsp90/Cdc37 interacts with the LKB1 kinase domain. Recently, Boudeau and colleagues reported that Hsp90/Cdc37 bind to mouse LKB1 and they further obtained evidence that this complex associates with the kinase domain of LKB1 , a finding in accordance with our own results. Interestingly, we repeatedly noticed that the amount of Hsp90 co-precipitated either with LKB1 deleted of the C-terminus (D317) or with LKB1 wild type was comparable, despite a consistent lower expression of the LKB1-D317 protein. This observation may indicate that the C-terminal domain of LKB1 is flexible and hinders the binding of Hsp90, thus providing a possible mechanism for controlling the dynamics of the LKB1 and Hsp90/ Cdc37 interactions.
Pharmacological inhibition of Hsp90 with GA and novobiocin was found to promote dissociation of the LKB1/Hsp90-Cdc37 complex and the subsequent degradation of LKB1. Metabolic labelling and pulse-chase experiments confirmed that GA induced a rapid dissociation of the Hsp90-LKB1 complex. In these experiments, the half-life of wild-type LKB1 was 2 h whereas the half-life of the LKB1-G163D mutant was 30 min, a result in agreement with the observed reduced affinity of Hsp90 to this mutant form of LKB1. The fundamental role of the proteasome in the control of protein turnover has now been firmly established Figure 6 Degradation of LKB1 is mediated by the proteasome. HBL100 cells transiently transfected with plasmid expressing Flag-LKB1 proteins were treated for 4 h in the presence of GA (lanes 3 and 10) or with the vehicle (DMSO, lanes 2 and 9). The proteasome inhibitor MG132 was added in the presence of either GA (lanes 4 and 11) or lysosomal protease inhibitors (Pepstatin, lanes 5 and 12 or its diluent methanol [MeOH] , lanes 6 and 13, and Leupeptin, lanes 7 and 14). Both soluble and insoluble fractions were analysed by Western blot using the anti-Flag M2 antibody (see experimental procedures for further details). T0 corresponds to the time before drug addition Figure 7 Dissociation of the LKB1-Hsp90 complex promotes LKB1 ubiquitination. (a) HBL100 cells were transiently transfected with a plasmid expressing Flag-LKB1 or cotransfected with plasmid expressing Flag-LKB1 and HA-ubiquitin (pHA-Ub). At 48 h post-transfection cells were treated during 16 h either by DMSO, GA, GA and MG132. Cells treated with these compounds were lysed and analysed by Western blot using the anti-Flag antibody (b) HBL100 cells transfected as described in the panel a were lysed, subjected to immunoprecipitation with the anti-Flag antibody and Western blotted with either an anti-ubiquitin antibody or the anti-Flag monoclonal antibody (Ciechanover and Schwartz, 1998) , therefore suggesting that the degradation of LKB1 might be regulated by this proteolytic pathway. Consistent with this idea, we found that GA-induced degradation of LKB1 was blocked with MG132, a specific inhibitor of the proteasome, whereas other protease inhibitors did not prevent LKB1 destabilization. Unexpectedly, MG132 induced an increase of the amount of LKB1 in the insoluble cellular fraction and not in the soluble cellular extracts. Similar findings have been reported for certain protein kinases which associate with Hsp90, such as MOK (Miyata et al., 2001 ) and PDK-1 (Fujita et al., 2002) , and this phenomenon is likely to reflect the fact that proteins which fail to be correctly folded aggregate in the insoluble fraction when both Hsp90 and the proteasome are inhibited. In agreement with our data, Boudeau and co-workers observed that either GA or another unrelated Hps90 inhibitor, radicicol, induce a decrease of the mouse LKB1 level which could be prevented by the addition of proteasome inhibitors .
Proteins fated to be degraded by the proteasome are tagged with polyubiquitin chains through the sequential action of E2 ubiquitin-conjugating enzymes and E3 ubiquitin ligases (Ciechanover and Schwartz, 1998) . Consistent with these biochemical processes, disruption of the LKB1/Hsp90 complex induced LKB1 ubiquitination and its subsequent degradation by the proteasome. It has been recently reported that the co-chaperone CHIP (carboxyl terminus of Hsc70-interacting protein) is an E3 ubiquitin ligase that promotes ubiquitination of Hsp90 client proteins such as the cystic fibrosis transmembrane-conductance regulator, glucocorticoid receptor and the Erb2 tyrosine kinase receptor (Ballinger et al., 1999; Connell et al., 2001; Jiang et al., 2001; Meacham et al., 2001) . By remodelling Hsp90 complexes, CHIP is involved in the protein triage system which controls the equilibrium between chaperonemediated protein refolding and degradation by the proteasome. It is thus conceivable that CHIP might be one of the E3 ligases that interacts with LKB1 and induces its ubiquitination when the heterocomplex Hsp90/LKB1 is dissociated, a question which warrants further investigation. Taken together, our results provide the first evidence that LKB1 turnover is regulated by the ubiquitin-proteasome proteolytic system. In summary, the data described in this study identify the molecular chaperones Hsp90 and Cdc37 as a major regulatory complex that binds to human LKB1 and regulates its stability. Our results suggest that Cdc37/ p50 is the targeting subunit which directly interacts with the LKB1 kinase domain as already demonstrated for several protein kinases (Hunter and Poon, 1997) . Furthermore, LKB1 catalytic activity was not required for its association with Hsp90/Cdc37. However, it is possible that Hsp90 assists the folding and the maturation of the LKB1 kinase domain. A classical example of the role of Hsp90 relates to its association with the steroid hormone receptors which is thought to maintain the receptor in a conformation competent for the binding of the hormone (Toft, 1999) . Similarly, it is conceivable that Hsp90 interaction with LKB1 induces a conformational change in LKB1 compatible with the loading of additional signalling partners such as p53, BRG-1 or LIP-1. Future experiments should examine the dynamics of the association and dissociation of the LKB1-Hsp90 complex, since it is plausible that the disassembly of this multiprotein complex might be physiologically relevant during the cell cyle, thus leading to the destruction of LKB1 and elimination of its growth arrest function.
One important consideration resulting from this research relates to the pharmacological inactivation of Hsp90 with drugs structurally related to GA, such as 17-allylaminogeldamycin (AAG) (Neckers, 2002) . This is a promising strategy in cancer therapeutics with AAG currently in phase I clinical trial (Neckers, 2002) . Our results suggest however that Hsp90 inhibitors may also elicit adverse clinical effects and favor the development of tumors by disrupting LKB1 tumor suppressor function, a question which needs to be carefully studied before wider clinical use of such compounds is implemented.
